UGT1A9 (human) MS2Plex&reg; assa

Confirm delete?

UGT1A9 (human) MS2Plex® assay kit

Zoom

Cat No: T05018

Assays - Ms2Plex Kits - Human Enzyme Udp Ugt

Price is excluding VAT and does not include packaging neither shipping

Human Enzyme UDP GlucuronosylTransferase (UGT) Assays UGTs are a family of enzymes not only capable of the detoxification and activation of drugs and xenobiotics, but are also involved in the metabolism of important endogenous substrates, e.g. bilirubi...

This article is not for sale online.
Contact us for more information about this article.

Product Overview
Data
Scientific Literature
Downloads
About MS2Plex

                        Territorial Availability: Available worldwide directly through Bertin Technologies or your local distributor
                    

Technical Warning: Human Enzyme UDP UGT Kits

Synonyms:

UGT1A9 (human) assay kit

Correlated keywords:

transporters

assays

BCRP

OATP

Product Overview:
Human Enzyme UDP GlucuronosylTransferase (UGT) Assays UGTs are a family of enzymes not only capable of the detoxification and activation of drugs and xenobiotics, but are also involved in the metabolism of important endogenous substrates, e.g. bilirubin or thyroid hormones. The biochemical characterization of the different isoforms is complicated due to the broad substrate specificity (and overlapping substrate affinities (i.e. one substrate is metabolized by more than one isoform). Glucuronidated compounds are susceptible to deconjugation by beta-glucuronidase, an enzyme that is widely distributed in mammalian tissues and localized intracellularly in lysosomes and endoplasmic reticulum. Combined actions of UGTs and beta-glucuronidase may play a role in futile cycling in which conjugated metabolites undergo successive cycles of synthesis to the glucuronide and hydrolysis back to the aglycone.

Size: 24 dtn

Shipping: Dry ice

Stability: Store at -80degrees; shelf life 6 months maximum after production

Specificity:

Enzyme UDP glucuronosyltransferase (UGT) (human)

Application Media: Microsomes, tissues extracts, cell membrane fractions

Sample volume: 50 μg of total protein

Detection Limit: at least 3 fmol/μg of total protein

Standard Curve Range: 3 to 300 fmol/µg of total protein

Custom Code: 3822000000

UNSPSC code: 41116104

Ohtsuki S., Uchida Y., Kubo Y., Terasaki T., Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: Methodology, advantages, strategy, and prospects, J. Pharm. Sci., 100: 3547–3559 (2011).

Kamiie J., Ohtsuki S., Iwase R., Ohmine K., Katsukura Y., Yanai K., Sekine Y., Uchida Y., Ito S., Terasaki T., Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res., 25: 1469-1483 (2008).

Sakamoto A., Matsumaru T., Ishiguro N., Schaefer O., Ohtsuki S., Inoue T., Kawakami H., Terasaki T., Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-Glucuronosyltranferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometer with nano-liquid chromatography, J. Pharm. Sci., 100: 4037–4043 (2011).

Kawakami H., Ohtsuki S., Kamiie J., Suzuki T., Abe T., Terasaki T., Simultaneous Absolute Quantifi cation of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection, J. Pharm. Sci., 100: 341–352 (2011).

Ohtsuki S., Schaefer O., Kawakami H., Inoue T., Liehner S., Sato A., Ishiguro N., Kishimoto W., Ludwig-Schwellinger E., Ebner T., and Terasaki T., Simultaneous absolute protein quantifi cation of transporters, Cytochrome P450s and UDP glucuronosyltransferases as a

novel approach for the characterization of individual human liver: Comparison with mRNA levels and activities. Drug Metab. Dispos., 40(1):83-92 (2012)

Shawahna R., Uchida Y., Decleves X., Ohtsuki S., Yousif S., Dauchy S., Jacob A., Chassoux F., Daumas C., Couraud PO., Terasaki T., Scherrmann JM., Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm., 8: 1332-1341 (2011).

Uchida Y., Ohtsuki S., Kamiie J., Terasaki T., Blood-Brain Barrier (BBB) Pharmacoproteomics (PPx): Reconstruction of In Vivo Brain Distribution of 11 Pglycoprotein Substrates based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice J. Pharmacol. Exp. Ther., 339: 579-588 (2011).

Technical File

MS2Plex® is a brand name of Bertin Bioreagent.
MS2Plex® comes from an original technology, developed by Professor Tetsuya Terasaki from Tohoku University, Sendai, Japan. MS2Plex® is a significant breakthrough in membrane protein analysis. This Quantitative Targeted Absolute Proteomics (QTAP) is based on the identification and separation of protein digests by liquid chromatography linked tandem mass spectrometry with multiple reaction monitoring. Bertin Bioreagent has signed a worldwide exclusive license for this patented technology.

To better serve you, we aim to design our products and reagents to address your needs on the expected performance in terms of a possible range of use, but also on operational conditions of use & regulations. Thanks to our production processes and quality controls, we provide you with products with compliance to specifications.
Our technical support & science teams are available to help you assess their relevance depending on your needs, to specify the conditions of application and their fields of use. Finally, our researchers are ready to provide you with the necessary support by going, if needed, in your laboratories to validate your operating conditions and to solve possible problems.

/ We also advise you

Cross selling for this product : UGT1A9 (human) MS2Plex® assay kit There are 10 products.